Following intra‐CSF treatment of patients with LM and breast cancer, survival has typically ranged from 2.9‐5.4 months,4, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and up to 13.6 months in HER2+ patients treated with intra‐CSF trastuzumab.25 The gene discussed is ERBB2; the disease is breast cancer.